Elevated intra-tumoral IL-6 levels in HNSCC are associated with advanced clinical staging, therapy resistance phenotypes, increased expression of programmed death-ligand 1 (PD-L1), and other immunosuppressive characteristics [49,67]. This evidence concerns the gene IL6 and head and neck squamous cell carcinoma.